By Tamara Mathias
Sept 20 (Reuters) - The U.S. Food and Drug Administration on Friday approved an oral version of Novo Nordisk's diabetes drug semaglutide, a boost for the Danish drugmaker which hopes to transform the market by offering patients a non-injectable treatment.
<u>Copenhagen-listed shares of the company rose 2.6% in late European trading.</u>
The world's biggest producer of diabetes drugs already sells an injectable once-weekly version of semaglutide under the brand name Ozempic at nearly $800 per month.
Novo did not disclose what it plans to charge for the new oral treatment, called Rybelsus, but said it would be "competitively priced" with other drugs in the same "GLP-1" class of medicines.
Eli Lilly and Co's Trulicity, an injectable rival, has a list price of $759.40 per month, according to Lilly's website. website
Rybelsus, which will be available in the United States in the fourth quarter, stimulates insulin production in patients with type 2 diabetes
Favorites
2,300
57:39
326
44:58
1,978
46:37